Search clinical trials for: immunotherapy with Nivolumab

Total 19383 results

University of Calgary

Completed

DBS for Treatment Resistant Depression (CRIO-DBS)

Depressive Disorder, Treatment-Resistant

Canada
Czech Lymphoma Study Group
Hoffmann-La Roche; Ministry of Health, Czech Republic

Completed

R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas (R-MCEB)

Diffuse Large B-Cell Lymphoma. | Primary Mediastinal B-Cell Lymphoma | Follicular Lymphoma Grade III

Czech Republic
Italian Network for Tumor Biotherapy Foundation
Bristol-Myers Squibb; Astex Pharmaceuticals, Inc.

Not yet recruiting

A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1)

Melanoma | Non Small Cell Lung Cancer

Italy
Peking University Cancer Hospital & Institute
Beijing Nanjiao Cancer Hospital

Recruiting

Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)

Rectal Cancer

China
Stallergenes Greer

Completed

Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract

Seasonal Allergic Rhinitis

Austria
Envita Medical Center, Inc.

Suspended

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

Glioma | Breast Cancer | Pancreatic Cancer | Prostate Cancer | Colon Cancer | Hepatocellular Cancer | Squamous Cell Lung Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7

United States
Bristol-Myers Squibb

Completed

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

France, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
Sun Yat-sen University

Recruiting

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Efficacy | Toxicity | Esophageal Squamous Cell Carcinoma

China
The Clatterbridge Cancer Centre NHS Foundation...
Bristol-Myers Squibb; University of Liverpool

Active, not recruiting

CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer (NICO)

Squamous Cell Carcinoma of the Oral Cavity

United Kingdom
Bristol-Myers Squibb

Not yet recruiting

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France (URADJ)

Urothelial Carcinoma

France
Meirav Kedmi MD

Recruiting

Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy (NivoM)

Lymphoma, B-Cell

Israel
Medical University of Warsaw

Not yet recruiting

Efficacy of Cashew Nut Protein Immunotherapy

Food Allergy

Poland
Sun Yat-sen University
Henan Cancer Hospital; Jiangmen Central Hospital

Completed

Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness

Lung Cancer

China
University Hospital, Geneva

Terminated

Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy

Peanut Allergy | Food Allergy

Switzerland
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Completed

Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer

Recurrent Breast Cancer

China
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Completed

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer

China
Stallergenes Greer

Completed

Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis

Allergy

Germany
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Recruiting

An Open-Label Phase II Study of Nivolumab in Adult Participants With Progessive/ Recurrent Meningioma

Meningiomas

United States
Hubei Cancer Hospital

Recruiting

Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later Line

Colorectal Neoplasms

China
Allergopharma GmbH & Co. KG

Completed

Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens

Pollen Allergy

Germany
Samuel Forrester Hunter, MD, PhD

Unknown

Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects

Multiple Sclerosis

United States
Erasmus Medical Center

Recruiting

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Immunotherapy | Melanoma Stage IV | Melanoma Stage III | Toxicity, Drug

Netherlands
Yonsei University

Recruiting

Nivolumab for Recurrent/Metastatic Carcinosarcoma

Recurrent/Metastatic Carcinosarcoma

Korea, Republic of
Bristol-Myers Squibb

Active, not recruiting

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Melanoma

Australia
Yonsei University

Completed

A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients

Non -Small Cell Lung Cancer

Korea, Republic of
University Hospital Tuebingen

Recruiting

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) (IT-PD1)

Leptomeningeal Disease

Germany
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Advanced Stage Non-small Cell Lung Cancer

United States
UNICANCER
Bristol-Myers Squibb

Completed

Nivolumab in Recurrent and/or Metastatic SCCHN (TopNIVO)

Recurrent and/or Metastatic Platinum-refractory SCCHN

France
Akamis Bio
Bristol-Myers Squibb; Syneos Health

Completed

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors (SPICE)

Colorectal Cancer | Squamous Cell Carcinoma of the Head and Neck | Epithelial Tumor

United States
Fukushima Medical University
Kanagawa Cancer Center

Unknown

Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)

Gastric Cancer

Japan
Asan Medical Center
Samsung Medical Center; Bundang CHA Hospital

Completed

Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma (RENOBATE)

Carcinoma, Hepatocellular | Hepatoma

Korea, Republic of
Amsterdam UMC, location VUmc
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction (NeoNivo)

Oral Cavity Squamous Cell Carcinoma

Netherlands
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home

Cancer | Solid Tumors

France
Hunan Province Tumor Hospital

Recruiting

Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy

Non Small Cell Lung Cancer

China
Sun Yat-sen University

Unknown

A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors

Nasopharyngeal Carcinoma | Hepatocellular Carcinoma | Breast Carcinoma

China
University Hospital, Basel, Switzerland
GMP network of Basel

Completed

Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma (BaseTIL)

Advanced Melanoma

Switzerland
Odense University Hospital

Recruiting

Long Term Effect of AIT in Children

Allergy in Children

Denmark
Xinqiao Hospital of Chongqing

Not yet recruiting

Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer

NSCLC | Radiotherapy | Immunotherapy | Intensity Modulated Radiation Therapy
Fujian Medical University

Not yet recruiting

Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma

Advanced Gastric Carcinoma | Neoadjuvant Immunotherapy | CD8+ Tumor Infiltrating Lymphocytes
Guy's and St Thomas' NHS Foundation Trust
King's College London; Imperial College London; National Institute for Health...

Completed

The Grown Up Peanut Immunotherapy Study (GUPI)

Peanut Allergy

United Kingdom
University of Oklahoma

Active, not recruiting

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population (SCC-ClinO+Ge)

Melanoma | Renal Cell Carcinoma | Nonsmall Cell Lung Cancer | Metastatic Solid Tumor | Gastrointestinal Cancer | Immune Checkpoint Inhibitors | Squamous Cell Carcinoma

United States
Hannover Medical School
Shields, Shields and Associates

Terminated

ORal IrON Supplementation With Ferric Maltol in Patients With Heart Failure Carrying Left Ventricular Assist Devices (ORION-LVAD-1)

Anemia, Iron Deficiency | Heart Failure, Left Sided

Germany
H. Lee Moffitt Cancer Center and Research Institute
University of Florida

Completed

Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)

Soft Tissue Sarcoma

United States
Lyudmila Bazhenova, M.D.
BeyondSpring Pharmaceuticals Inc.

Active, not recruiting

Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer Metastatic

United States
Clinica Universidad de Navarra, Universidad de...

Unknown

Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST)

Neoplasms

Spain
Royal Marsden NHS Foundation Trust

Unknown

A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR) (ADAPTeR)

Renal Cell Carcinoma

United Kingdom
PharmaEssentia

Recruiting

The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection

Chronic Hepatitis B Infection | Chronic Hepatitis D Infection

Taiwan
Weill Medical College of Cornell University
Bristol-Myers Squibb

Active, not recruiting

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

Gastroesophageal Adenocarcinoma

United States
Bristol-Myers Squibb

Completed

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies (MDX1106-01)

Carcinoma, Non-Small-Cell Lung | Colorectal Cancer | Prostate Cancer | Renal Cancer | Malignant Melanoma

United States

Search clinical trials for: immunotherapy with Nivolumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations